ResearchResearch summary
Nystatin for presumed Candida-related systemic symptoms
A 42-woman crossover trial found no meaningful advantage over placebo for systemic or psychological symptoms.
In this pathway
- Current topic
- Nystatin for presumed Candida-related systemic symptomsCurrent
Bottom line
Nystatin did not improve systemic or psychological symptoms meaningfully more than placebo, although it improved vaginal symptoms.
Why this source matters
It directly tested a historically influential broad Candida treatment claim under blinded placebo control.
Study and population
The 32-week crossover trial included 42 premenopausal women with a history of Candida vaginitis who met a historical syndrome definition.
What was tested
Participants received four combinations of oral or vaginal nystatin and matching placebo, with vaginal, systemic, psychological, and overall symptoms measured.
Results
Systemic symptoms improved 25% with nystatin-containing regimens and 23% with all-placebo, a 2-point difference with a 95% confidence interval from -3 to 7 points. Vaginal symptoms improved more with nystatin.
Applicability
The result applies to nystatin and the trial's narrow historical population, not every antifungal or recognized localized and invasive candidiasis.
Limitations
Only 42 women participated, the syndrome definition is historical, and the result cannot adjudicate other interventions.
Contribution to the evidence
Contradictory. The controlled result contradicts a systemic-symptom benefit claim for nystatin while preserving the separate vaginal finding.
Practical change
No practical change. This paper alone cannot change guidance, and it does not support empirical long-term nystatin for the tested broad syndrome.
Funding and conflicts
Funding came from the Critical Illness Research Foundation and named NIH/NIAID support. No author financial conflict statement was reported in the accessible record.
Source
Read the original publication record (published 20 December 1990).
Study type, population, and sample scale
- Study type
- Randomized double-blind 32-week crossover trial of oral and vaginal nystatin and matching placebos
- Population
- 42 premenopausal women who met the study's then-current criteria for presumed candidiasis hypersensitivity syndrome and had a history of Candida vaginitis
- Sample scale
- 42 participants in a four-regimen oral and vaginal active-treatment or placebo crossover
Results
- Mean systemic-symptom scores improved by 25% across the three nystatin-containing regimens and by 23% with all-placebo, a 2-percentage-point difference (95% confidence interval -3 to 7 percentage points).
- Nystatin-containing regimens relieved vaginal symptoms more than placebo, but systemic symptoms, psychological symptoms, and global distress did not improve significantly more than placebo among the 42 participants.
Limitations
- Nystatin did not outperform placebo for systemic or psychological symptoms.
- The crossover trial included only 42 premenopausal women and tested nystatin under a historical syndrome definition.
- Vaginal symptoms improved more with active nystatin.
- A localized vaginal-symptom effect does not establish that Candida caused the systemic symptoms.
Applies to
- The tested nystatin regimens and systemic-symptom claim in the narrowly defined 1990 trial population
Does not apply to
- Every antifungal, recognized localized or invasive candidiasis, modern diagnostic criteria, or people outside the studied population
Contribution to the current conclusion
Contradictory
The randomized placebo-controlled result directly tests a historically influential broad Candida treatment claim; a summary can separate the null systemic and psychological outcomes from the improvement in vaginal symptoms and avoid overgeneralizing beyond nystatin.
Related evidence mapPractical change or no change
No practical change. The trial does not support long-term nystatin for the tested broad systemic-symptom syndrome, while its result must not be generalized to other drugs or recognized candidiasis.
Funding and conflicts
- Funding
- Critical Illness Research Foundation, NIH General Clinical Research Center grant DRR00032, and NIAID contract N01-AI-52562.
- Conflicts
- No author financial conflict statement was reported in the accessible article record.
- Paper date
- 1990-12-20
Sources
View all 1 source
- A randomized, double-blind trial of nystatin therapy for the candidiasis hypersensitivity syndrome
- Source type
- Randomized trial
- Published
- 1990-12-20